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Background
Multiple studies have shown that dendritic cell (DC)-based
vaccines can induce antitumor immunity. Previously, we
reported that gemcitabine enhances the efficacy of DC
vaccination in a mouse model of pancreatic carcinoma.
The present study aimed at investigating the influence of
gemcitabine on vaccine-induced anti-tumoral immune
responses in a syngeneic pancreatic cancer model.
Material and methods
Subcutaneous or orthotopic pancreatic tumours were
induced in C57BL/6 mice using Panc02 cells expressing
the model antigen OVA (PancOVA). Bone marrow-
derived DC were loaded with soluble OVA protein
(OVA-DC). Animals received gemcitabine twice weekly.
OVA-specific CD8
+ T cells and antibody titers were
monitored by FACS analysis and ELISA, respectively.
Results
Gemcitabine enhanced clinical efficacy of the OVA-DC
vaccine. Interestingly, gemcitabine significantly suppressed
the vaccine-induced frequency of antigen-specific CD8
+
T cells and antibody titers. DC migration to draining
lymph nodes and antigen cross-presentation were unaf-
fected. Despite reduced numbers of tumour-reactive
T cells in peripheral blood, in vivo cytotoxicity assays
revealed that CTL-mediated killing was preserved. In vitro
assays revealed sensitization of tumour cells to CTL-
mediated lysis by gemcitabine. In addition, gemcitabine
facilitated recruitment of CD8
+ T cells into tumors in
DC-vaccinated mice. T and B cell suppression by gemcita-
bine could be avoided by starting chemotherapy after two
cycles of DC vaccination.
Conclusions
Gemcitabine enhances therapeutic efficacy of DC vacci-
nation despite its negative influence on vaccine-induced
T cell proliferation. Quantitative analysis of tumour-
reactive T cells in peripheral blood may thus not predict
vaccination success in the setting of concomitant
chemotherapy.
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